13,16-dioxaoctacosane | 22870-18-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 13,16-dioxaoctacosane
• 英文别名: 1,2-bis-dodecyloxy-ethane；1,2-Bis-dodecyloxy-aethan；Glycol-di-dodecylether；1-[2-(Dodecyloxy)ethoxy]dodecane；1-(2-dodecoxyethoxy)dodecane
• CAS: 22870-18-4
• 化学式: C₂₆H₅₄O₂
• 分子量: 398.714
• InChiKey: PISUYKADQNVTGH-UHFFFAOYSA-N

物化性质

• 沸点：
  467.0±18.0 °C(Predicted)
• 密度：
  0.847±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.1
• 重原子数：
  28
• 可旋转键数：
  25
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(氯甲氧基)十二烷 在 铜 作用下， 生成 13,16-dioxaoctacosane
  参考文献：
  名称：

  Teramura; Oda, Kogyo Kagaku zasshi / Journal of the Society of Chemical Industry, 1951, vol. 54, p. 604,606

  摘要：

  DOI：

文献信息

• Synthesis of some acyclic quaternary ammonium compounds. Alkylation of secondary and tertiary amines in a two-phase system
  作者：A. V. Kharlamov、O. I. Artyushin、N. A. Bondarenko

  DOI：10.1007/s11172-014-0761-x

  日期：2014.11

  and asymmetrical quaternary ammonium chlorides of the general formula R1R2R3N+AR4Cl– (R1 = Me, Bu; R2 = n-C12H25, PhCH2, CnH2n+1(OCH2CH2)m, n = 9 and 12, m = 1 and 2; R3 = n-C12H25, PhCH2, HOCH2CH2,–OOCCH2; R4 = n-C12H25, PhCH2; A = (CH2CH2O)1,2, CH2C(O)O) was synthesized by the alkylation of tertiary amines in a two-phase system containing water. A convenient method for the synthesis of the initial

  通式R1R2R3N+AR4Cl–（R1 = Me, Bu; R2 = n-C12H25, PhCH2, CnH2n+1(OCH2CH2)m, n = 9 and 12, m = 1）的一系列无环对称和不对称季铵氯化物和 2; R3 = n-C12H25, PhCH2, HOCH2CH2,–OOCCH2; R4 = n-C12H25, PhCH2; A = (CH2CH2O)1,2, CH2C(O)O) 是通过叔胺的烷基化合成的相系统含水。一种合成通式 MeNR1R2 的初始对称和不对称叔胺的简便方法（R1 = Me, Bu；R2 = n-C12H25, PhCH2, CnH2n+1(OCH2CH2)m, n = 9 和 12, m = 1 和 2) 在有机相-水相非均相系统中被开发出来，它允许使用碱和胺的水溶液。
• [EN] METHODS OF ETHERIFICATION<br/>[FR] PROCÉDÉS D'ÉTHÉRIFICATION
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：WO2021067077A1

  公开（公告）日：2021-04-08

  Embodiments of the present disclosure are directed towards methods of etherification including reducing templates of a zeolite catalyst to provide a reduced template zeolite catalyst having from 3 to 15 weight percent weight percent of templates maintained following calcination of zeolite catalyst; and contacting the reduced template zeolite catalyst with an olefin and an alcohol to produce a monoalkyl ether.

  本公开的实施例涉及醚化方法，包括将沸石催化剂的模板还原以提供具有从3至15重量百分比的模板的还原模板沸石催化剂，在沸石催化剂煅烧后保持模板；并将还原模板沸石催化剂与烯烃和醇接触以产生单烷基醚。
• Production process for (poly) alkylene glycol monoalkyl ether
  申请人：NIPPON SHOKUBAI CO., LTD.

  公开号：EP0846671A2

  公开（公告）日：1998-06-10

  The present invention provides a process for producing a (poly)alkylene glycol monoalkyl ether with high selectivity and high yield. In this process, the (poly)alkylene glycol monoalkyl ether is produced by reacting an olefin and a (poly)alkylene glycol in the presence of a catalyst, wherein: 1) a crystalline metallositicate is used as the catalyst, and at least a portion of the used catalyst is regenerated, and the regenerated catalyst is recycled as the catalyst for the reaction; or 2) the reaction between the olefin and the (poly)alkylene glycol is carried out in the presence of either or both of a (poly)alkylene glycol dialkyl ether and an alcohol.

  本发明提供了一种具有高选择性和高产率的（聚）亚烷基二醇单烷基醚的生产工艺。在该工艺中，(聚)亚烷基二醇单烷基醚是通过烯烃和(聚)亚烷基二醇在催化剂存在下反应制得的，其中：1) 使用结晶型金属锡酸盐作为催化剂，使用过的催化剂至少有一部分被再生，再生的催化剂作为反应催化剂被循环使用；或 2) 烯烃和（聚）亚烷基二醇之间的反应在（聚）亚烷基二醇二烷基醚和醇中的一种或两种存在下进行。
• TRANSDERMALLY ABSORPTIVE PREPARATION
  申请人：Cosmed Pharmaceutical Co., Ltd.

  公开号：EP2233142A1

  公开（公告）日：2010-09-29

  Summary This invention is to provide a transdermal administration type pharmaceutical preparation which has better transdermal absorptivity, safty and practical application for treatment of bone calcium metabolic diseases, such as high calcium in blood which resulted from osteoporosis, osteitis deformans and malignant tumors. A percutaneous administration type pharmaceutical preparation in tape form comprising a flexible backing, which is not permeable by the active ingredient, and an adhesive base layer formed on said flexible backing; said adhesive base layer consisting essentially of an adhesive base material of acrylic copolymer, polyhydric alcohol and bisphosphonate or its derivatives, wherein the bisphosphonate or its derivatives are in their therapeutic dose, adhesive base material and polyhydric alcohol in a concenrtration ratio of 100 : 150 to 600 by weight; said acrylic copolymer are copolymerized by acrylic acid, 2-ethylhexyl acrylate and polar monomer (except for acrylic acid) in the concentration ratio of 50 to 88% : 8 to 40% : 1 to 40% by weight respectively. PEG modify and antioxidants are also applicable to reduce the skin stimulation.

  摘要 本发明旨在提供一种透皮给药型药物制剂，该药物制剂具有较好的透皮吸收性、安全性和实用性，可用于治疗骨钙代谢性疾病，如骨质疏松症引起的高血钙、变形性骨炎和恶性肿瘤等。 一种经皮给药型药物制剂，胶带状，包括不被活性成分渗透的柔性衬底和在所述柔性衬底上形成的粘合剂基底层；所述粘合剂基底层主要由丙烯酸共聚物、多元醇和双膦酸盐或其衍生物的粘合剂基底材料组成，其中双膦酸盐或其衍生物的治疗剂量、粘合剂基底材料和多元醇的重量比为 100 ：所述丙烯酸共聚物由丙烯酸、丙烯酸 2-乙基己酯和极性单体（丙烯酸除外）按重量比分别为 50%至 88%∶8%至 40%∶1%至 40%的比例共聚而成。PEG 改性剂和抗氧化剂也可用于减少对皮肤的刺激。
• TIRE AND METHOD OF EVALUATING TIRE GRIP PERFORMANCE
  申请人：Sumitomo Rubber Industries, Ltd.

  公开号：EP3848209A1

  公开（公告）日：2021-07-14

  The present invention aims to provide tires which exhibit satisfactory grip performance both before and after running-in. The present invention relates to tires including a tread rubber, the tread rubber satisfying the following relationship (I): a/b≥0.75 wherein the symbols (a) and (b) represent the minimum and maximum Martens hardnesses, respectively, of a tire tread contact portion measured in a region from 10 µm to 200 µm deep in the tire radial direction from the tire surface.

  本发明旨在提供在磨合前和磨合后均表现出令人满意的抓地性能的轮胎。本发明涉及包括胎面橡胶的轮胎，胎面橡胶满足以下关系（I）：a/b≥0.75 其中，符号（a）和（b）分别代表轮胎胎面接触部分的最小和最大马顿硬度，测量区域为轮胎径向距离轮胎表面深度从 10 微米到 200 微米的区域。